Your browser doesn't support javascript.
loading
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens, Corneel; Suciu, Stefan; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Celeste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bottomley, Andrew; Kotapati, Srividya; de Pril, Veerle; Testori, Alessandro; Eggermont, Alexander M M.
Afiliação
  • Coens C; EORTC Headquarters, Brussels, Belgium. Electronic address: corneel.coens@eortc.be.
  • Suciu S; EORTC Headquarters, Brussels, Belgium.
  • Chiarion-Sileni V; IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy.
  • Grob JJ; Hôpital de la Timone, Marseille, France.
  • Dummer R; University of Zürich Hospital, Zürich, Switzerland.
  • Wolchok JD; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schmidt H; Aarhus University Hospital, Aarhus, Denmark.
  • Hamid O; The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
  • Robert C; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
  • Ascierto PA; Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Richards JM; Oncology Specialists S C, Park Ridge, IL, USA.
  • Lebbé C; Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Paris.
  • Ferraresi V; Istituti Fisioterapici Ospitalieri, Rome, Italy.
  • Smylie M; Cross Cancer Institute, Edmonton, AB, Canada.
  • Weber JS; H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Maio M; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
  • Bottomley A; EORTC Headquarters, Brussels, Belgium.
  • Kotapati S; Bristol-Myers Squibb, Wallingford, CT, USA.
  • de Pril V; Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
  • Testori A; European Institute of Oncology, Milan, Italy.
  • Eggermont AMM; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Lancet Oncol ; 18(3): 393-403, 2017 03.
Article em En | MEDLINE | ID: mdl-28162999
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Adjuvantes Imunológicos / Melanoma / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Adjuvantes Imunológicos / Melanoma / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article